SRI Awarded National Cancer Institute Drug Support Contract; Toufan Parman Comments
SRI International will provide preclinical treatment development support for the National Cancer Institute’s Prevent Cancer Drug Development Program under a potential $9 million contract. NCI’s Prevent initiative aims to advance the development of biomarkers and drug candidates designed to prevent cancer and transition them from preclinical phase to clinical trials, SRI said Monday. Toufan Parman, […] More